Congestive heart failure

Pharmacological agents and the potential of B-type natriuretic peptide

Kenneth D. James, Alessandro Cataliotti, John A. Schirger, Shannon Plonka, John C Jr. Burnett

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Congestive heart failure (CHF) is a life-threatening cardiovascular disease that is increasing in prevalence. It is a common cause of death and is accompanied by high direct and indirect costs for treatment. The current situation faced by patients and the medical community with regard to this ailment is one of high mortality, repeated hospitalizations, and combination therapies. The various classes of pharmacological agents that are currently used for patients suffering from CHF include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists, beta-blockers, calcium channel blockers (CCBs), digitalis drugs, diuretics, inotropic agents, nitrates, and vasodilators. While these agents are all important therapeutic tools in the treatment of CHF, the prognosis for patients with CHF remains poor. Thus improvement of the current pharmacological armamentarium is greatly needed. An endogenous peptide, B-type natriuretic peptide (BNP), has been increasingly utilized in the setting of acute CHF since its approval in 2001. This peptide, or a derivative thereof, has great potential for the treatment of patients at various stages in the progression of heart failure This review provides an overview of current pharmacological strategies in CHF and addresses potential future developments in the use of BNP for the treatment of CHF.

Original languageEnglish (US)
Pages (from-to)1439-1447
Number of pages9
JournalCurrent Medicinal Chemistry
Volume12
Issue number12
DOIs
StatePublished - 2005

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Pharmacology
Mineralocorticoid Receptor Antagonists
Therapeutics
Digitalis
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Health Care Costs
Nitrates
Peptides
Cause of Death
Hospitalization
Cardiovascular Diseases
Derivatives
Mortality
Pharmaceutical Preparations

Keywords

  • BNP
  • Congestive heart failure
  • Natriuretic peptide
  • Nesiritide

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Organic Chemistry
  • Pharmacology

Cite this

Congestive heart failure : Pharmacological agents and the potential of B-type natriuretic peptide. / James, Kenneth D.; Cataliotti, Alessandro; Schirger, John A.; Plonka, Shannon; Burnett, John C Jr.

In: Current Medicinal Chemistry, Vol. 12, No. 12, 2005, p. 1439-1447.

Research output: Contribution to journalArticle

James, Kenneth D. ; Cataliotti, Alessandro ; Schirger, John A. ; Plonka, Shannon ; Burnett, John C Jr. / Congestive heart failure : Pharmacological agents and the potential of B-type natriuretic peptide. In: Current Medicinal Chemistry. 2005 ; Vol. 12, No. 12. pp. 1439-1447.
@article{d2d54d70e7a642c3a35a442fd8aeacff,
title = "Congestive heart failure: Pharmacological agents and the potential of B-type natriuretic peptide",
abstract = "Congestive heart failure (CHF) is a life-threatening cardiovascular disease that is increasing in prevalence. It is a common cause of death and is accompanied by high direct and indirect costs for treatment. The current situation faced by patients and the medical community with regard to this ailment is one of high mortality, repeated hospitalizations, and combination therapies. The various classes of pharmacological agents that are currently used for patients suffering from CHF include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists, beta-blockers, calcium channel blockers (CCBs), digitalis drugs, diuretics, inotropic agents, nitrates, and vasodilators. While these agents are all important therapeutic tools in the treatment of CHF, the prognosis for patients with CHF remains poor. Thus improvement of the current pharmacological armamentarium is greatly needed. An endogenous peptide, B-type natriuretic peptide (BNP), has been increasingly utilized in the setting of acute CHF since its approval in 2001. This peptide, or a derivative thereof, has great potential for the treatment of patients at various stages in the progression of heart failure This review provides an overview of current pharmacological strategies in CHF and addresses potential future developments in the use of BNP for the treatment of CHF.",
keywords = "BNP, Congestive heart failure, Natriuretic peptide, Nesiritide",
author = "James, {Kenneth D.} and Alessandro Cataliotti and Schirger, {John A.} and Shannon Plonka and Burnett, {John C Jr.}",
year = "2005",
doi = "10.2174/0929867054020909",
language = "English (US)",
volume = "12",
pages = "1439--1447",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Congestive heart failure

T2 - Pharmacological agents and the potential of B-type natriuretic peptide

AU - James, Kenneth D.

AU - Cataliotti, Alessandro

AU - Schirger, John A.

AU - Plonka, Shannon

AU - Burnett, John C Jr.

PY - 2005

Y1 - 2005

N2 - Congestive heart failure (CHF) is a life-threatening cardiovascular disease that is increasing in prevalence. It is a common cause of death and is accompanied by high direct and indirect costs for treatment. The current situation faced by patients and the medical community with regard to this ailment is one of high mortality, repeated hospitalizations, and combination therapies. The various classes of pharmacological agents that are currently used for patients suffering from CHF include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists, beta-blockers, calcium channel blockers (CCBs), digitalis drugs, diuretics, inotropic agents, nitrates, and vasodilators. While these agents are all important therapeutic tools in the treatment of CHF, the prognosis for patients with CHF remains poor. Thus improvement of the current pharmacological armamentarium is greatly needed. An endogenous peptide, B-type natriuretic peptide (BNP), has been increasingly utilized in the setting of acute CHF since its approval in 2001. This peptide, or a derivative thereof, has great potential for the treatment of patients at various stages in the progression of heart failure This review provides an overview of current pharmacological strategies in CHF and addresses potential future developments in the use of BNP for the treatment of CHF.

AB - Congestive heart failure (CHF) is a life-threatening cardiovascular disease that is increasing in prevalence. It is a common cause of death and is accompanied by high direct and indirect costs for treatment. The current situation faced by patients and the medical community with regard to this ailment is one of high mortality, repeated hospitalizations, and combination therapies. The various classes of pharmacological agents that are currently used for patients suffering from CHF include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists, beta-blockers, calcium channel blockers (CCBs), digitalis drugs, diuretics, inotropic agents, nitrates, and vasodilators. While these agents are all important therapeutic tools in the treatment of CHF, the prognosis for patients with CHF remains poor. Thus improvement of the current pharmacological armamentarium is greatly needed. An endogenous peptide, B-type natriuretic peptide (BNP), has been increasingly utilized in the setting of acute CHF since its approval in 2001. This peptide, or a derivative thereof, has great potential for the treatment of patients at various stages in the progression of heart failure This review provides an overview of current pharmacological strategies in CHF and addresses potential future developments in the use of BNP for the treatment of CHF.

KW - BNP

KW - Congestive heart failure

KW - Natriuretic peptide

KW - Nesiritide

UR - http://www.scopus.com/inward/record.url?scp=21044458028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044458028&partnerID=8YFLogxK

U2 - 10.2174/0929867054020909

DO - 10.2174/0929867054020909

M3 - Article

VL - 12

SP - 1439

EP - 1447

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 12

ER -